Drug Profile
Research programme: human monoclonal antibody therapeutics - Mitsubishi Chemical Corporation
Latest Information Update: 26 May 2010
Price :
$50
*
At a glance
- Originator Mitsubishi Chemical
- Class Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 26 May 2010 Discontinued - Preclinical for Cancer in Japan (unspecified route)
- 02 May 2006 Preclinical trials in Cancer in Japan (unspecified route)